StockData
BioMarin Pharmaceutical Inc logo

BioMarin Pharmaceutical Inc (BMRN) stock

BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 8/30145% above fair value
$58.51+1.02 (+1.77%)

Close on Oct 30, 2026Market cap $11.33BP/E 154.0Yield –

Earnings

BioMarin Pharmaceutical's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 22, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$990.00M
+20.0% on a year earlier
Non-GAAP Diluted EPS, Q2 FY2026
$1.20
$1.44 a year earlier
Latest guidance
Raised
Aug 6, 2026 · 5 items

Quarterly results

Revenue and earnings per share from each of BioMarin Pharmaceutical's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 22, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Oct 6, 2026after the close––––Filing
Q2 FY2026ended Jun 30, 2026Aug 6, 2026after the close$990.00M+20.0%$0.23$1.20Release
Q1 FY2026ended Mar 31, 2026May 4, 2026after the close$766.00M+2.8%$0.54$0.76Release
Q4 FY2025ended Dec 31, 2025Feb 23, 2026after the close$875.00M+17.1%-$0.24$0.46Release
Q3 FY2025ended Sep 30, 2025Oct 27, 2025after the close$776.00M+4.0%-$0.16$0.12Release
Q2 FY2025ended Jun 30, 2025Aug 4, 2025after the close$825.00M+15.9%$1.23$1.44Release
Q1 FY2025ended Mar 31, 2025May 1, 2025after the close$745.00M+14.8%$0.95$1.13Release
Q4 FY2024ended Dec 31, 2024Feb 19, 2025after the close$747.00M+15.6%$0.64$0.92Release
Q3 FY2024ended Sep 30, 2024Oct 29, 2024after the close$746.00M+28.3%$0.55$0.91Release
Q2 FY2024ended Jun 30, 2024Aug 5, 2024after the close$712.00M+19.6%$0.55$0.96Release
Q1 FY2024ended Mar 31, 2024Apr 24, 2024after the close$648.80M+8.8%$0.46$0.71Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

BioMarin Pharmaceutical's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Total RevenuesFY2026$3.88B – $3.93B$975.00M – $1.03BRaisedAug 6, 2026
Total RevenuesGAAPFY2026$3.33B – $3.43B–NewFeb 23, 2026
Non-GAAP Operating Marginnon-GAAPFY202640%40%ReaffirmedFeb 23, 2026
Non-GAAP Diluted EPSnon-GAAPFY2026$4.90 – $5.10–NewAug 6, 2026
Non-GAAP Diluted EPSnon-GAAPFY2026$4.95 – $5.15–NewFeb 23, 2026
Total RevenuesFY2027$4.00B$4.00BReaffirmedFeb 19, 2025
operating cash flow per yearFY2027$1.25B–NewOct 29, 2024
operating cash flowsFY2027$1.25B–ReaffirmedFeb 19, 2025

Guidance history

Every forecast BioMarin Pharmaceutical put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 6, 2026Non-GAAP Diluted EPSFY2026$4.90 – $5.10New
Aug 6, 2026Total RevenuesFY2026$3.88B – $3.93BRaised
Aug 6, 2026Metabolic ConditionsFY2026$2.73B – $2.78BLowered
Aug 6, 2026VOXZOGOFY2026$1.00B – $1.05BLowered
Aug 6, 2026Other RevenuesFY2026$100.00M – $125.00MLowered
May 4, 2026VOXZOGOFY2026$975.00M – $1.03BNew
May 4, 2026Other RevenuesFY2026$100.00M – $125.00MLowered
Feb 23, 2026Non-GAAP Diluted EPSFY2026$4.95 – $5.15New
Feb 23, 2026Non-GAAP Operating MarginFY202640%Reaffirmed
Feb 23, 2026Total RevenuesFY2026$3.33B – $3.43BNew
Oct 27, 2025Non-GAAP Diluted EPSFY2025$3.50 – $3.60Lowered
Oct 27, 2025Non-GAAP Operating Margin %FY202526% – 27%Lowered
Oct 27, 2025Total RevenuesFY2025$3.15B – $3.20BNew
Aug 4, 2025Non-GAAP Diluted EPSFY2025$4.40 – $4.55Raised
Aug 4, 2025Non-GAAP Operating Margin %FY202533% – 34%Raised
Aug 4, 2025Total RevenuesFY2025$3.13B – $3.20BRaised
Aug 4, 2025VOXZOGO contribution to full-year 2025 Total RevenuesFY2025$900.00M – $935.00MLowered
May 1, 2025Non-GAAP Diluted EPSFY2025$4.20 – $4.40Reaffirmed
May 1, 2025Non-GAAP Operating Margin %FY202532% – 33%Reaffirmed
May 1, 2025Total RevenuesFY2025$3.10B – $3.20BRaised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases BioMarin Pharmaceutical filed with the SEC as exhibits to Form 8-K or 6-K

  1. BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on
    Update
  2. BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia,
    Update
  3. BioMarin Reports Second Quarter 2026 Financial and Operating Results
    Results
  4. Report of Independent Registered Public Accounting Firm
    News
  5. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
    News
  6. BioMarin Reports First Quarter 2026 Financial and Operating Results
    Results
  7. BioMarin Completes Acquisition of Amicus Therapeutics
    Update
  8. BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
    Results
  9. BioMarin Announces Closing of Private Offering of Senior Notes
    Update
  10. BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of
    Update
  11. BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan
    Results
  12. Risks Related to the Acquisition
    Results
  13. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
    Results
  14. Hardy Greg Friberg Chief Executive Officer Chief R&D Officer BioMarin Pharmaceutical Inc. January 12, 2026
    Results
  15. BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and
    Update